Expected Revenue Growth:
[294 Pages Report] The global infectious disease diagnostics market size is projected to reach USD 33.1 billion by 2027 from USD 35.5 billion in 2022, at a -1.4% CAGR.
Download PDF Brochure @ https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=116764589
What This Report Will Provide?
This study involved four major activities in estimating the current size of the infectious disease diagnostics market. Exhaustive secondary research was carried out to collect information on the market, its peer markets, and its parent market.
The next step was to validate these findings, assumptions, and sizing with industry experts across the value chain through primary research. Both top-down and bottom-up approaches were employed to estimate the complete market size.
Major Growth Boosters:
The global prevalence of infectious diseases and the growing awareness for early disease diagnosis, shift in focus from centralized laboratories to decentralized POC testing and rising technological advancements are factors supporting the growth of this market.
COVID-19 Impact on Global Infectious Disease Diagnostics Market
COVID-19 is an infectious disease caused by the novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 a pandemic on March 11, 2020.
Regional Growth Analysis:
The infectious disease diagnostics market is segmented into five regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2021, North America accounted for the largest share of the infectious disease diagnostics market. The large share of this region can be attributed to the highly developed healthcare system in the US and Canada, the presence of many leading national clinical laboratories, and the easy accessibility to technologically advanced instruments.
Key Market Players
The major players operating in this market are Abbott Laboratories (US), Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), bioMérieux SA (France), Siemens Healthineers AG (Germany), Danaher Corporation (US), Becton, Dickinson and Company (US), PerkinElmer, Inc. (US), Hologic, Inc. (US), QIAGEN N.V. (Netherlands), Grifols S.A. (Spain), DiaSorin S.p.A (Italy), Bio-Rad Laboratories, Inc. (US), Sysmex Corporation (Japan), Ortho Clinical Diagnostics Holdings plc
Request Sample Report: https://www.marketsandmarkets.com/requestsampleNew.asp?id=116764589
Recent Developments
· In November 2022, Roche Diagnostics Launched cobas 5800 system.
· In February 2021, Thermo Fisher Scientific acquired Mesa Biotech (US) to expand the benefits of molecular diagnostics at the point of care.
· In March 2020, Abbott Laboratories launched the ID NOW COVID-19 Test.
Frequently Asked Questions (FAQ):
· What are the challenges affecting the infectious disease diagnostics market?
· What are the different types of testing in the infectious disease diagnostics market?
· Who are the key players in the infectious disease diagnostics market?
· Who are the key end-users of the infectious disease diagnostics market?
· Which region is lucrative for the infectious disease diagnostics market?
To speak to our analyst for a discussion on the above findings : https://www.marketsandmarkets.com/speaktoanalystNew.asp?id=116764589
